Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).
The results of this study are not yet available.
You can participate in this study for as long as your study doctor determines that you are benefiting from the study treatment.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of Gastric Cancer (gastric or gastroesophageal junction adenocarcinoma (GEJ) adenocarcinoma)
Participant must have disease progression during or within 4 months after last dose of first-line chemotherapy
Participant must have received combination chemotherapy
Male participants must be sterile or agree to use a reliable method of birth control
Female participants of child-bearing potential must have a negative pregnancy test and agree to use a highly effective method of birth control; all other female participants must be surgically sterile or postmenopausal
Participant must not have known brain metastases or leptomeningeal disease
Participant must not have a history of gastrointestinal perforation or fistula within 6 months
Participant must not have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months
Participant must not have Child-pugh B, C cirrhosis or HIV